```html

Kidd’s Disease (Amyloidosis) – A Complete Patient‑Friendly Guide

Overview

Kidd’s disease is a colloquial name sometimes used for systemic amyloidosis that predominantly affects the kidneys. The condition occurs when abnormal protein fragments, called amyloid, misfold and deposit in various organs, impairing their normal function. While “Kidd’s disease” is not an official medical term, it is occasionally referenced in older renal literature to describe amyloid nephropathy first described by pediatric nephrologist Dr. Thomas Kidd.

In practice, the term most clinicians use is amyloidosis, which can be divided into several subtypes:

• AL (light‑chain) amyloidosis – caused by plasma‑cell disorders such as multiple myeloma.
• AA (secondary) amyloidosis – related to chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease).
• ATTR (transthyretin) amyloidosis – hereditary or wild‑type (age‑related) forms.

Kidney involvement is common across subtypes, and when renal disease is the dominant manifestation, clinicians may refer to it as “renal amyloidosis” or “Kidd’s disease.”

Who it affects: Amyloidosis can occur at any age, but the distribution varies by type.

• AL amyloidosis: median age 65 years; slightly more common in men.
• AA amyloidosis: often affects adults 40–70 years old with long‑standing inflammatory conditions.
• ATTR hereditary: can appear in the 30s–50s, depending on the genetic mutation.

Prevalence: Exact numbers are difficult because the disease is rare and often under‑diagnosed.

• Overall incidence of systemic amyloidosis in the United States is estimated at 8–10 cases per million per year (Mayo Clinic, 2022).
• Renal amyloidosis accounts for ~30–40% of systemic cases, making “Kidd’s disease” an uncommon but clinically important entity.

Symptoms

The clinical picture depends on which organs have amyloid deposits. When the kidneys are primarily involved, the following signs and symptoms are typical:

Renal (Kidney) Symptoms

• Proteinuria – frothy urine due to excess protein loss; often the first clue.
• Nephrotic syndrome – a combination of heavy proteinuria (>3.5 g/day), low blood albumin, swelling (edema), and high cholesterol.
• Reduced kidney function – rising serum creatinine and declining glomerular filtration rate (GFR).
• Hematuria – blood in urine, less common but may occur.

Cardiac Symptoms (when amyloid also involves the heart)

• Shortness of breath on exertion or at rest.
• Fatigue and decreased exercise tolerance.
• Irregular heartbeat or heart block.
• Peripheral edema that worsens despite diuretics.

Gastrointestinal Symptoms

• Unexplained weight loss.
• Diarrhea or constipation.
• Feeling of early satiety.

Neurologic and Peripheral Nerve Symptoms

• Numbness, tingling, or burning sensations in the feet and hands (peripheral neuropathy).
• Carpal tunnel syndrome – common early manifestation of ATTR amyloidosis.

Other Systemic Signs

• Dry, waxy skin with easy bruising.
• Enlarged tongue (macroglossia) – classic but seen in only 15–20% of AL cases.
• Unexplained fatigue, anemia, and low blood pressure.

Causes and Risk Factors

Amyloidosis is not a single disease but a group of disorders linked by the misfolding of specific proteins. Understanding the underlying cause helps guide therapy.

Primary (AL) Amyloidosis

• Plasma‑cell dyscrasia – abnormal plasma cells produce excess light chains (λ or κ) that misfold.
• Associated conditions: Multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS).

Secondary (AA) Amyloidosis

• Chronic inflammatory or infectious diseases stimulate the liver to produce serum amyloid A (SAA) protein.
• Major risk factors: Rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, chronic infections (e.g., tuberculosis, osteomyelitis), and familial Mediterranean fever.

ATTR Amyloidosis

• Mutations in the transthyretin (TTR) gene → unstable TTR protein.
• Wild‑type ATTR (formerly “senile systemic amyloidosis”) occurs with age, especially in men over 70.

Other Rare Forms

• Beta‑2 microglobulin amyloidosis – occurs in patients on long‑term dialysis.
• Familial amyloid polyneuropathy – due to mutations in other genes (e.g., GSN, FGA).

General Risk Factors

• Age > 60 years (most subtypes).
• Male sex (ATTR wild‑type, AL).
• Long‑standing inflammatory disease or chronic infection.
• Family history of hereditary amyloidosis.
• Exposure to certain chemicals (e.g., silica) – limited data.

Diagnosis

Because symptoms are often nonspecific, a high index of suspicion is essential. Diagnosis generally proceeds in three steps: clinical suspicion, tissue confirmation, and subtype identification.

1. Laboratory Screening

• Urine protein electrophoresis (UPEP) & 24‑hour urine protein – quantifies protein loss.
• Serum protein electrophoresis (SPEP) with immunofixation – detects monoclonal light chains.
• Serum free light‑chain assay – highly sensitive for AL amyloidosis.
• Acute‑phase reactants (CRP, ESR) – often elevated in AA amyloidosis.
• Kidney function tests – serum creatinine, eGFR.

2. Imaging

• Renal ultrasound – may show enlarged, hyperechoic kidneys.
• Cardiac MRI or echocardiography – assesses wall thickness, diastolic dysfunction (common in cardiac amyloid).
• 99mTc‑PYP (pyrophosphate) scan – non‑invasive test that lights up in ATTR cardiac amyloidosis.

3. Tissue Biopsy

The definitive diagnosis requires a biopsy demonstrating amyloid deposits, typically using Congo red staining with apple‑green birefringence under polarized light.

• Kidney biopsy – gold standard when renal disease dominates.
• Abdominal fat pad aspiration – minimally invasive; positive in ~70% of AL cases.
• Bone‑marrow biopsy – to evaluate plasma‑cell burden.

4. Subtype Determination

• Mass spectrometry or immunohistochemistry on biopsy tissue – identifies the amyloid protein (AL, AA, ATTR, etc.).
• Genetic testing – sequencing of the TTR gene for hereditary ATTR, and other relevant genes when indicated.

5. Staging & Assessment of Organ Involvement

Staging systems (e.g., Mayo 2012 cardiac staging for AL amyloidosis) help predict prognosis and guide therapy. Comprehensive assessment includes:

• Cardiac biomarkers (NT‑proBNP, troponin).
• Liver function tests.
• Neurologic evaluation for peripheral neuropathy.

Treatment Options

Treatment strategies differ by amyloid subtype and organ involvement. The overarching goals are to stop further amyloid production, clear existing deposits when possible, and support affected organs.

1. AL (Light‑Chain) Amyloidosis

• Plasma‑cell directed therapy
  • Combination regimens such as CyBorD (cyclophosphamide, bortezomib, dexamethasone).
  • Autologous stem‑cell transplant (ASCT) for eligible patients (<10–15% of cases).
  • Newer agents – daratumumab (anti‑CD38 monoclonal antibody) has shown survival benefit (Mayo Clinic, 2023).
• Supportive kidney care – ACE inhibitors/ARBs for proteinuria, diuretics for edema, and early referral for renal replacement therapy if eGFR < 30 mL/min/1.73 m².

2. AA (Secondary) Amyloidosis

• Treat the underlying inflammatory disease – biologics (e.g., TNF‑α inhibitors for rheumatoid arthritis) dramatically reduce SAA levels.
• Colchicine – especially effective in familial Mediterranean fever to prevent attacks and amyloid formation.
• Renal protective measures similar to AL amyloidosis.

3. ATTR Amyloidosis

• TTR stabilizers
  • Diflunisal (non‑steroidal anti‑inflammatory) – off‑label use.
  • FDA‑approved tafamidis (Vyndaqel) – improves survival and reduces cardiovascular events.
• Gene‑silencing therapies
  • Patisiran (RNAi) and inotersen (antisense) – reduce hepatic TTR production; approved for hereditary ATTR polyneuropathy.
• Liver transplantation – curative for some hereditary TTR mutations (less common now with newer drugs).

4. General Supportive Care

• Diuretics and dietary sodium restriction for edema.
• ACE inhibitors/ARBs – lower proteinuria and slow renal progression.
• Nutrition – high‑protein diet only if kidney function permits; otherwise a renal‑friendly diet with adequate calories.
• Physical activity – low‑impact aerobic exercise improves stamina without overtaxing the heart.
• Psychosocial support – counseling, support groups, and mental‑health resources.

Living with Kidd’s Disease (Amyloidosis)

Managing a chronic, multisystem illness requires practical day‑to‑day strategies.

Medication Management

• Keep an up‑to‑date medication list; use a weekly pill organizer.
• Never skip chemotherapy cycles or biologic infusions; missing doses can accelerate organ damage.
• Report new side‑effects (e.g., neuropathy from bortezomib) promptly.

Kidney‑Specific Tips

• Monitor blood pressure at home; aim for <130/80 mmHg unless otherwise advised.
• Check urine dipstick weekly for protein or blood.
• Stay well‑hydrated (unless fluid‑restricted due to heart failure); typical 2–2.5 L/day.
• Discuss dialysis options early if eGFR declines below 20 mL/min/1.73 m².

Dietary Guidance

• Limit sodium to <2 g/day to control edema.
• If proteinuria is heavy, restrict dietary protein to 0.6–0.8 g/kg body weight (consult a renal dietitian).
• Increase omega‑3 fatty acids (fish oil) – may have anti‑inflammatory benefits.
• Avoid excess alcohol, which can worsen heart and liver involvement.

Activity & Lifestyle

• Aim for 150 minutes of moderate aerobic activity per week (e.g., walking, stationary cycling).
• Incorporate gentle strength training twice weekly to preserve muscle mass.
• Practice stress‑reduction techniques – mindfulness, yoga, or tai chi.

Monitoring & Follow‑up

• Quarterly labs: serum creatinine, eGFR, albumin, complete blood count, and disease‑specific markers (e.g., free light chains, NT‑proBNP).
• Annual cardiac evaluation (echo or MRI) even if asymptomatic.
• Regular ophthalmology and neurology visits if peripheral neuropathy or visual changes develop.

Emotional & Social Support

• Join national amyloidosis foundations (e.g., Amyloidosis Foundation, AL Innovations) for education and peer support.
• Consider professional counseling to address anxiety or depression, which affect up to 30% of patients (Cleveland Clinic, 2022).

Prevention

Because many forms of amyloidosis are driven by underlying diseases, prevention focuses on controlling those triggers.

• Control chronic inflammation – adhere to disease‑modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis or IBD.
• Treat infections promptly – especially tuberculosis and chronic osteomyelitis.
• Screen high‑risk families for hereditary TTR mutations; early detection enables prophylactic therapy.
• Maintain healthy lifestyle habits – avoid smoking, keep blood pressure and blood sugar in target ranges, and stay physically active.

Complications

If left untreated or poorly managed, amyloidosis can lead to serious, potentially life‑threatening complications.

• End‑stage renal disease (ESRD) – requires dialysis or kidney transplant; occurs in ~30–40% of renal amyloid patients within 5 years.
• Cardiac failure – restrictive cardiomyopathy is the leading cause of death in AL amyloidosis.
• Arrhythmias & conduction blocks – may necessitate pacemaker implantation.
• Gastrointestinal bleeding – due to mucosal amyloid, leading to anemia.
• Peripheral neuropathy – can become disabling and increase fall risk.
• Thromboembolic events – especially in patients with atrial involvement.
• Infections – immunosuppressive therapies increase susceptibility.

When to Seek Emergency Care

---

© 2024 HealthGuide Media. All information provided is for educational purposes and does not replace professional medical advice. For personalized care, please consult your physician or a qualified health‑care provider.

Key References

• Mayo Clinic. “Systemic Amyloidosis.” Updated 2022. https://www.mayoclinic.org/
• Cleveland Clinic. “Amyloidosis Treatment Options.” 2023. https://my.clevelandclinic.org/
• National Institutes of Health. “AL Amyloidosis.” 2022. https://www.nhlbi.nih.gov/
• World Health Organization. “Guidelines for Management of Chronic Inflammatory Diseases.” 2021.
• American Heart Association. “Cardiac Amyloidosis.” 2023. https://www.heart.org/

```